Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis

NCT01218581 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis

Interventions

DRUG: received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)

Sponsor

Mansoura University